Advisory board

Khusru Asadullah

Khusru Asadullah

Khusru Asadullah, MD, is Professor of Medicine at the department of Dermatology, Charité - Berlin Medical School, Chairman of the Management Board of German Skin Research Center, board certified consultant for Dermatology, Venerology, Allergology and Immunology, former Vice-President Target Discovery at Bayer-Schering Pharma.
Read more

Rita Balice-Gordon

Rita Balice-Gordon

Rita Balice-Gordon, Ph.D., is the Chief Scientific Officer of Muna Therapeutics. She is leading the development of novel therapeutics for neurodegenerative diseases.
Read more

C. Glenn Begley

C. Glenn Begley

Dr Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development.
Read more

Prof Ulrich Dirnagl

Prof Ulrich Dirnagl

Ulrich Dirnagl, MD, PhD, is the Director of the Department of Experimental Neurology at the Charité Universitätsmedizin Berlin, Chief Executive Director of the Center for Stroke Research Berlin, Clinical program coordinator of the Excellence Cluster NeuroCure and...
Read more

Dario Doller

Dario Doller

Dario earned a Ph.D. in Organic Chemistry from the Facultad de Ciencias Exactas y Naturales, UBA, Argentina. He conducted postdoctoral studies with Sir Derek Barton at Texas A&M University. He is currently Director, Medicinal Chemistry at Sunovion Pharmaceuticals.
Read more

Magali Haas

Magali Haas

Magali Haas is CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in Cambridge, MA. She previously served as founding Chief Science and Technology Officer for One Mind for Research.
Read more

Prof Malcolm Macleod

Prof Malcolm Macleod

Malcolm Macleod, BSc(Hons) MBChB PhD FRCP Ed, is Professor of Neurology and Translational Neuroscience at the University of Edinburgh, head of Neurology at Forth Valley Royal Hospital, and Honorary Principal Research Fellow, Florey Neurosciences Unit, Melbourne, Australia.
Read more

Phil Skolnick

Phil Skolnick

Dr. Skolnick is the Chief Scientific Officer at Opiant Pharmaceuticals, Inc. Prior to joining Opiant, he was the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017).
Read more

Thomas Steckler

Thomas Steckler

Thomas Steckler, MD, is Associate Director, Bioresearch Quality & Compliance, Preclinical Quality Risk Management and global Bioresearch Quality & Compliance Lead Animal Welfare, Janssen Pharmaceutica NV, Belgium.
Read more